VISIFLEX
Report
- Report Number
- 2031527-2015-00468
- Event Type
- Injury
- Date Received
- November 30, 2015
- Date of Event
- October 31, 2015
- Report Date
- October 29, 2015
- Manufacturer
- ENDOLOGIX
- Product Code
- MIH
- PMA / PMN Number
- P040002
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- MI, US
- Reporter Occupation
- 1
Narratives
THE DEVICE INVOLVED IN THE EVENT WILL NOT BE RETURNED FOR EVALUATION AS IT REMAINS IMPLANTED IN THE PATIENT. IF ADDITIONAL INFORMATION PERTINENT TO THE INCIDENT IS OBTAINED, A FOLLOW-UP REPORT WILL BE SUBMITTED. MODEL # AND LOT # OF OTHER INVOLVED DEVICE: MODEL#: 28-28-75L, INT'L VISTIFLEX; LOT #: W08-0803-014; DOM: (B)(6) 2008; EXPIRATION: 04/30/2011.
BASED UPON THE CLINICAL ASSESSMENT, THE REPORTED TYPE IIIIA ENDOLEAK WAS CONFIRMED. THERE WAS ALSO EVIDENCE OF COMPLETE COMPONENT SEPARATION. THE MANUFACTURING RECORD REVIEW DID NOT REVEAL ANY ISSUES OR DEVIATIONS THAT WOULD EXPLAIN THE REPORTED EVENT. BASED UPON THE INVESTIGATION, THE ROOT CAUSE COULD NOT BE DEFINITELY DETERMINED ALTHOUGH PATIENT ANATOMY WAS THE LIKELY CAUSE OF COMPONENT SEPARATION AND THE RESULTING ENDOLEAK. THERE WAS NO DESIGN OR MANUFACTURING ISSUE IDENTIFIED. THE CLINICAL REVIEW IDENTIFIED THE FOLLOWING FACTORS THAT MAY HAVE BEEN CONTRIBUTORS TO THE EVENT: THE REPORTED 90° ANGULATION OF THE INFRARENAL AORTA; THE INABILITY TO TOLERATE CONTRASTED SURVEILLANCE (SOME FOLLOW-UP STUDIES DID NOT INCLUDE CONTRAST); THE USE OF CONCOMITANT NON-ENDOLOGIX BARE METAL STENTS WITHIN THE PROXIMAL AORTA; AND THE USE OF ANTIPLATELET THERAPY (ASPIRIN AND PLAVIX).
IT WAS REPORTED THE PATIENT HAD AN INITIAL PROCEDURE ON (B)(6) 2008 WITH A BIFURCATED AND TWO CUFF STENT GRAFTS. REPORTEDLY, THE PATIENT EXPERIENCED PAIN IN THE LEFT LEG COMPUTED TOMOGRAPHY REVEALED AN ENDO.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 785021 | VISIFLEX | STENT GRAFT | MIH | ENDOLOGIX | 28-28-75L-US VISIFLEX | W08-0023-006 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 89 YR | Required Intervention |